New AsiDNA e-Poster Now Online at AACR Virtual Meeting 2020

Preclinical Data Confirm the Ability of AsiDNA to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells

PARIS, June 22, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the availability on the AACR 2020 Virtual meeting website of the e-poster and its audio commentary presenting new preclinical data supporting the differentiated ability of AsiDNA, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing regrowth of death-tolerant cells (DTC).

These new data show for the first time that PARPi resistance can be caused by drug-tolerant cells, and that the addition of AsiDNA to PARP inhibitors prevents the regrowth of these cells, thereby completely and irreversibly abolishing the emergence of resistance in ovarian tumor cells.

These results bode well for the upcoming Phase 1b/2 REVocan study, combining AsiDNA with niraparib in the clinical setting in recurrent ovarian cancer, which has been approved by regulatory authorities in France and is expected to start in the second half of 2020.

Moreover, these data clearly reinforce the interest of AsiDNA in the fight against acquired resistance to cancer treatments, which is the main challenge in oncology today.

Session: PO.ET03.04 - Mechanisms of sensitivity and resistance to DNA damage repair targeting

Date/Time: June 22-24, 2020 - 9:00 AM - 6:00 PM (U.S. Eastern Daylight Time - EDT)

E-poster: 4078 / 8

• Read the abstract on the AACR website: Acquired resistance to PARP inhibitors evolves from drug-tolerant persister cells vulnerable to AsiDNA
  
  
• Access the e-poster
  
  
• Access its audio commentary

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.